Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.

Despite the successes provided by vaccination, many challenges still exist with respect to controlling new and re-emerging infectious diseases. Innovative vaccine platforms composed of adaptable adjuvants able to appropriately modulate immune responses, induce long-lived immunity in a single dose, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bret D Ulery, Devender Kumar, Amanda E Ramer-Tait, Dennis W Metzger, Michael J Wannemuehler, Balaji Narasimhan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/aca5fd4e39604ce3940a2e932b897511
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aca5fd4e39604ce3940a2e932b897511
record_format	dspace
spelling	oai:doaj.org-article:aca5fd4e39604ce3940a2e932b8975112021-11-18T06:57:48ZDesign of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.1932-620310.1371/journal.pone.0017642https://doaj.org/article/aca5fd4e39604ce3940a2e932b8975112011-03-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21408610/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Despite the successes provided by vaccination, many challenges still exist with respect to controlling new and re-emerging infectious diseases. Innovative vaccine platforms composed of adaptable adjuvants able to appropriately modulate immune responses, induce long-lived immunity in a single dose, and deliver immunogens in a safe and stable manner via multiple routes of administration are needed. This work describes the development of a novel biodegradable polyanhydride nanoparticle-based vaccine platform administered as a single intranasal dose that induced long-lived protective immunity against respiratory disease caused by Yesinia pestis, the causative agent of pneumonic plague. Relative to the responses induced by the recombinant protein F1-V alone and MPLA-adjuvanted F1-V, the nanoparticle-based vaccination regimen induced an immune response that was characterized by high titer and high avidity IgG1 anti-F1-V antibody that persisted for at least 23 weeks post-vaccination. After challenge, no Y. pestis were recovered from the lungs, livers, or spleens of mice vaccinated with the nanoparticle-based formulation and histopathological appearance of lung, liver, and splenic tissues from these mice post-vaccination was remarkably similar to uninfected control mice.Bret D UleryDevender KumarAmanda E Ramer-TaitDennis W MetzgerMichael J WannemuehlerBalaji NarasimhanPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 3, p e17642 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bret D Ulery Devender Kumar Amanda E Ramer-Tait Dennis W Metzger Michael J Wannemuehler Balaji Narasimhan Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
description	Despite the successes provided by vaccination, many challenges still exist with respect to controlling new and re-emerging infectious diseases. Innovative vaccine platforms composed of adaptable adjuvants able to appropriately modulate immune responses, induce long-lived immunity in a single dose, and deliver immunogens in a safe and stable manner via multiple routes of administration are needed. This work describes the development of a novel biodegradable polyanhydride nanoparticle-based vaccine platform administered as a single intranasal dose that induced long-lived protective immunity against respiratory disease caused by Yesinia pestis, the causative agent of pneumonic plague. Relative to the responses induced by the recombinant protein F1-V alone and MPLA-adjuvanted F1-V, the nanoparticle-based vaccination regimen induced an immune response that was characterized by high titer and high avidity IgG1 anti-F1-V antibody that persisted for at least 23 weeks post-vaccination. After challenge, no Y. pestis were recovered from the lungs, livers, or spleens of mice vaccinated with the nanoparticle-based formulation and histopathological appearance of lung, liver, and splenic tissues from these mice post-vaccination was remarkably similar to uninfected control mice.
format	article
author	Bret D Ulery Devender Kumar Amanda E Ramer-Tait Dennis W Metzger Michael J Wannemuehler Balaji Narasimhan
author_facet	Bret D Ulery Devender Kumar Amanda E Ramer-Tait Dennis W Metzger Michael J Wannemuehler Balaji Narasimhan
author_sort	Bret D Ulery
title	Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
title_short	Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
title_full	Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
title_fullStr	Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
title_full_unstemmed	Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
title_sort	design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/aca5fd4e39604ce3940a2e932b897511
work_keys_str_mv	AT bretdulery designofaprotectivesingledoseintranasalnanoparticlebasedvaccineplatformforrespiratoryinfectiousdiseases AT devenderkumar designofaprotectivesingledoseintranasalnanoparticlebasedvaccineplatformforrespiratoryinfectiousdiseases AT amandaeramertait designofaprotectivesingledoseintranasalnanoparticlebasedvaccineplatformforrespiratoryinfectiousdiseases AT denniswmetzger designofaprotectivesingledoseintranasalnanoparticlebasedvaccineplatformforrespiratoryinfectiousdiseases AT michaeljwannemuehler designofaprotectivesingledoseintranasalnanoparticlebasedvaccineplatformforrespiratoryinfectiousdiseases AT balajinarasimhan designofaprotectivesingledoseintranasalnanoparticlebasedvaccineplatformforrespiratoryinfectiousdiseases
_version_	1718424125681172480

Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.

Ejemplares similares